ArticleCureus2026
An In-Field Recurrent Cervical Cancer Case After Chemoradiotherapy With a Marked Response to Pembrolizumab Combined With TC (Paclitaxel-Carboplatin) Therapy: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent cervical cancer after definitive concurrent chemoradiotherapy (CCRT), particularly in-field recurrence, is associated with poor prognosis and limited curative options. The efficacy of immune checkpoint inhibitor therapy combined with chemotherapy in this setting remains unclear. We report the case of a 32-year-old woman with in-field recurrent cervical squamous cell carcinoma (SCC) following definitive CCRT. The recurrent tumor was PD-L1 positive (combined positive score (CPS) ≥1). She received combination therapy with paclitaxel, carboplatin, and pembrolizumab. Marked tumor regression was observed, and the triplet regimen was continued for 16 cycles due to ongoing clinical benefit, followed by pembrolizumab monotherapy for a total of 35 cycles. The patient maintained good performance status, without severe adverse events, and remains recurrence-free 10 months after treatment completion. Pembrolizumab combined with TC (paclitaxel-carboplatin) therapy may be an effective treatment option for selected patients with unresectable in-field recurrent cervical cancer. Further evidence is required to clarify the optimal duration of combination therapy and the timing of transition to immune checkpoint inhibitor maintenance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.